^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Excerpt:
...Histologically or cytologically confirmed, locally advanced and/or metastatic IIIB, IIIC or IV non-squamous NSCLC or recurrent non-squamous NSCLC（according to the 8th Edition of the AJCC Staging system）with EGFR 19 del and/or 21 L858R gene mutation 4....
Trial ID:
Source:
Title:
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
Excerpt:
...Signed and dated informed consent 18-75years，ECOG PS：0-2，Life expectancy of more than 3 months，with measurable lesion ( RECIST1.1) Histologically or cytologically confirmed, locally advanced and/or metastatic IIIB, IIIC or IV non-squamous NSCLC or recurrent non-squamous NSCLC（according to the 8th Edition of the AJCC Staging system）with EGFR 19 del or 21 L858R gene mutation and concomitant others....
Trial ID:
More C2 evidence
Source:
Title:
A multicenter, randomized, double-blind, parallel-controlled clinical trial for Anlotinib plus Icotinib versus placebo plus Icotinib in the treatment of stage IIIB-IV EGFR gene-sensitive mutant non-small cell lung cancer patients
Excerpt:
...1) Subjects voluntarily joined the study and signed informed consent; 2) Male or female patients between the ages of 18-75 years; 3) ECOG PS 0-1 points; 4) The expected survival period more than 3 months; 5) Pathologically confirmed IIIB (not suitable for radiotherapy), stage IV non-small cell lung cancer, with measurable lesions (according to RECIST 1.1, CT scan long diameter 10mm, lymph node lesion CT scan short diameter >= 15mm, The measurable lesions have not received local treatment such as radiotherapy or freezing); 6) According to any validated method, the patient has a EGFR activating mutation (exon 19 deletion or 21L858R point mutation) in primary non-small cell lung cancer; 7) Have not received chemotherapy or other targeted therapies in the past; Note: The treatment used in the neoadjuvant treatment phase is not included in the treatment plan; the recurrence within 6 months after the end of adjuvant therapy is defined as first-line treatment and cannot be included in the study; more than 6 months of recurrence, adjuvant treatment Not included in the treatment plan. ...
Trial ID:
Less C2 evidence
Source:
Title:
1219P-Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004
Published date:
09/13/2021
Excerpt:
The mPFS was 15.600 months (95%CI: 10.407-20.793) and 14.900 months (95%CI: 9.089-20.711) of patients with concomitant mutation and pathogenic concomitant mutation, respectively. Patients with concomitant mutation or pathogenic concomitant mutation achieved ORR more than 80%, DCR 100% and ETS greater than 70%....This updated analysis has confirmed that anlotinib plus icotinib showed encouraging efficacy for untreated, EGFR-mutated advanced NSCLC patients and may represent a new treatment option for patients with concomitant mutations.
Trial ID:
Source:
Title:
1342P - Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study
Published date:
09/14/2020
Excerpt:
Patients with EGFR-mutated locally advanced and/or metastatic stage IIIb-IV non-squamous NSCLC were enrolled….This updated analysis has confirmed that A plus T showed encouraging efficacy for previously untreated, EGFR-mutated advanced NSCLC patients.
Trial ID:
